|
|
 |
|
VOLUME 66 |
2005 |
NUMBER 10 |
To ensure continued delivery, please add MedFair@MedFair.com to your address book.
Prevalence, Correlates, and Comorbidity of Bipolar I Disorder and Axis I and II Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Bridget F. Grant, Frederick S. Stinson, Deborah S. Hasin, Deborah A. Dawson, S. Patricia Chou, W. June Ruan, and Boji Huang
Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder. Jeffrey S. Simon and Charles B. Nemeroff
Paroxetine Response and Tolerability Among Ethnic Minority Patients With Mood or Anxiety Disorders: A Pooled Analysis. Peter P. Roy-Byrne, Philip Perera, Cornelius D. Pitts, and Jacquie A. Christi
Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to Antidepressants. Linda L. Carpenter, Nada Milosavljevic, Jordan M. Schecter, Audrey R. Tyrka, and Lawrence H. Price
Diagnostic Stability 18 Months After Treatment Initiation for First-Episode Psychosis. Benno G. Schimmelmann, Philippe Conus, Jane Edwards, Patrick D. McGorry, and Martin Lambert
Dissociative Disorders Among Inpatients With Drug or Alcohol Dependency. Figen Karadag, Vedat Sar, Defne Tamar-Gurol, Cuneyt Evren, Mustafa Karagoz, and Murat Erkiran
A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder. Stuart A. Montgomery, Rico Nil, Natalie Dürr-Pal, Henrik Loft, and Jean-Philippe Boulenger
Associations of Anxiety-Related Symptoms With Reported History of Childhood Sexual Abuse in Schizophrenia Spectrum Disorders. Paul H. Lysaker, Louanne W. Davis, Michael J. Gatton, and Steven M. Herman
Reduction of Opioid-Withdrawal Symptoms With Quetiapine. Harold B. Pinkofsky, Ann M. Hahn, Frances A. Campbell, John Rueda, Dennis C. Daley, and Antoine B. Douaihy
Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. Richard C. Shelton, Douglas J. Williamson, Sara A. Corya, Todd M. Sanger, Luann E. Van Campen, Michael Case, Susan D. Briggs, and Gary D. Tollefson
Open-Label Study of Atypical Neuroleptic Quetiapine for Treatment of Borderline Personality Disorder: Impulsivity as Main Target. Evens Villeneuve and Sophie Lemelin
Predictors of Everyday Functioning Among Older Mexican Americans vs. Anglo-Americans With Schizophrenia. Neelum D. Jeste, David J. Moore, Sherrill R. Goldman, Jesus Bucardo, Wendy Davila-Fraga, Shahrokh Golshan, Dilip V. Jeste, and Thomas L. Patterson
Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. Aytekin Sir, Russell F. D'Souza, Sukru Uguz, Tom George, Simavi Vahip, Malcolm Hopwood, Andrew J. Martin, William Lam, and Tal Burt
Adjunctive Risperidone in Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study. Olga Brawman-Mintzer, Rebecca G. Knapp, and Paul J. Nietert
Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder. George I. Papakostas, Timothy J. Petersen, Gustavo Kinrys, Alana M. Burns, John J. Worthington III, Jonathan E. Alpert, Maurizio Fava, and Andrew A. Nierenberg
Prevalence and Features of Intermittent Explosive Disorder in a Clinical Setting.[CME] Emil F. Coccaro, Michael A. Posternak,and Mark Zimmerman
Sleep and Depression.[CME] Norifumi Tsuno, Alain Besset, and Karen Ritchie
Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story? Christoph U. Correll
Addition of Lamotrigine to Clozapine in Inpatients With Chronic Psychosis. Adolph H. Heck, Izaäk W. de Groot, and Peter N. van Harten
Is There a Real Difference Between the First Onset of Efficacy for Atypical Antipsychotic Monotherapies in Acute Bipolar Mania? Tamas Treuer and Bruce R. Basson · Reply by Paul E. Keck, Jr.
Thyroid Dysfunction During Treatment With Atypical Antipsychotics. Andrew Greenspan, Georges Gharabawi, and Joseph Kwentus
Weight Gain, Sexual Dysfunction, and Bupropion. Michael J. Menaster · Reply by Mark Zimmerman, Michael A. Posternak, Naureen Attiullah, Michael Friedman, Robert J. Boland, Scott Baymiller, Stacie Lauro Berlowitz, Shahzad Rahman, Kirsten K. Uy, Steve Singer, Iwona Chelminski, and Tavi Thongy
Treatment-Emergent Psychosis With Aripiprazole. Matthew E. Barnas, Najeeb Hussain, and Georgios Petrides
The Creation of Psychopharmacology. Reviewed by Theodore A. Petti.
Early Intervention for Trauma and Traumatic Loss. Reviewed by Theodore A. Petti. |
